Baseline Prognostic Factors and Statistic Model to Predict Early Virological Response in Telbivudine-Treated Patients With Chronic Hepatitis B

BACKGROUND: Hepatitis B virus (HBV) infection is still a worldwide disease, which may cause liver cirrhosis or even hepatocellular carcinoma. Telbivudine is a potent nucleoside analogue used in the treatment of chronic hepatitis B (CHB); however, drug resistance has remained a challenge. As early vi...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Rui, Zhou, Yuan-Ping, Lin, Chun, Gao, Hai-bing, Huang, Shui-wen, Huang, Zu-xiong, Sun, Fang, Lin, Yong, Zhang, Dong-qing, Lin, Qing-feng, Ao, Wen, Pan, Chen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Kowsar 2013
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3877653/
https://www.ncbi.nlm.nih.gov/pubmed/24403918
http://dx.doi.org/10.5812/hepatmon.15573

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3877653/
https://www.ncbi.nlm.nih.gov/pubmed/24403918
http://dx.doi.org/10.5812/hepatmon.15573

Ejemplares similares